Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Realizing the potential of plasma genotyping in an age of genotype-directed therapies.

Journal of the National Cancer Institute - 1 Aug 2014

Luke Jason J, Oxnard Geoffrey R, Paweletz Cloud P, Camidge D Ross, Heymach John V, Solit David B, Johnson Bruce E

Abstract excerpt

The identification of oncogenic driver mutations in cancer has led to the rapid rise of genotype-directed treatments such as EGFR and BRAF kinase inhibitors. Standard tumor biopsy remains a cumbersome and morbid procedure for patients, leading to a growing interest in noninvasive plasma genotyping approaches. Circulating tumor cells are of interest; however, the processing of specimens is complicated and time...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Neoplasms

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 25106647
DOI: 10.1093/jnci/dju214
PMCID: PMC6281080

Genes

BRAF
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Realizing the potential of plasma genotyping in an age of genotype-directed therapies.PMID 25106647Read ↗

Cell-Free DNA in Oncology: Gearing up for Clinic.Semantic proximity Read ↗

A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.Semantic proximity Read ↗

Application of Cell-Free DNA Analysis to Cancer TreatmentSemantic proximity Read ↗

Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Quantitative measurement of cell-free plasma DNA and applications for detecting tumor genetic variation and promoter methylation in a clinical setting.Semantic proximity Read ↗

The use of cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) to guide treatment selection in metastatic breast cancer.Semantic proximity Read ↗

Circulating free DNA in the era of precision oncology: Pre‐ and post‐analytical concernsSemantic proximity Read ↗

Clinical Testing for Tumor Cell-Free DNA: College of American Pathologists Proficiency Programs Reveal Practice Trends.Semantic proximity Read ↗

Using circulating cell-free DNA to monitor personalized cancer therapySemantic proximity Read ↗

Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging TechnologiesSemantic proximity Read ↗

Is Cell-Free DNA Testing in Hepatocellular Carcinoma Ready for Prime Time?Semantic proximity Read ↗

Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sampleSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.